Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ: CGEM )

11.60 +0.65 (+5.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed... 
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.